| Bioactivity | FABPs ligand 6 (MF6) is an FABP5 and FABP7 inhibitor with KD values of 874 nM and 20 nM, respectively. FABPs ligand 6 can be used for multiple sclerosis research[1]. |
| Target | KD: 20 nM (FABP7), 874 nM (FABP5) |
| Invitro | FABPs ligand 6 (MF6) rescues mitochondrial function by blocking voltagedependent anion channel (VDAC)-1-dependent mitochondrial macropore formation induced by psychosine in KG-1C cells, a FABP5- mediated injury[1]. |
| In Vivo | MF 6 (1 mg/kg; i.g.; daily for 4 weeks) improves the severity of EAE (experimental autoimmune encephalomyelitis) and attenuates oxidative levels and the inflammatory response[1]. Animal Model: |
| Name | FABPs ligand 6 |
| Formula | C28H27FN2O3 |
| Molar Mass | 458.52 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Cheng A, et al. A novel fatty acid-binding protein 5 and 7 inhibitor ameliorates oligodendrocyte injury in multiple sclerosis mouse models. EBioMedicine. 2021 Oct;72:103582. |